Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Point Therapeutics Inc (POTP) since 2010 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Point Therapeutics Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 919745.
Total stock buying since 2010: $180,632.
Total stock sales since 2010: $0.
Total stock option exercises since 2010: $0.
▪ Recent SEC 13D filings for all companies
▪ Recent portfolio reports of all companies
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2013 | 59,000 | $41,912 | 0 | $0 | 0 | $0 |
| 2012 | 90,000 | $79,611 | 0 | $0 | 0 | $0 |
| 2011 | 3,500 | $9,730 | 0 | $0 | 0 | $0 |
| 2010 | 16,096 | $49,379 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2013-06 | 14,000 | $9,982 | 0 | $0 | 0 | $0 |
| 2013-05 | 45,000 | $31,930 | 0 | $0 | 0 | $0 |
| 2012-09 | 30,000 | $30,512 | 0 | $0 | 0 | $0 |
| 2012-07 | 10,000 | $7,324 | 0 | $0 | 0 | $0 |
| 2012-06 | 25,000 | $19,250 | 0 | $0 | 0 | $0 |
| 2012-05 | 25,000 | $22,525 | 0 | $0 | 0 | $0 |
| 2011-04 | 3,500 | $9,730 | 0 | $0 | 0 | $0 |
| 2010-09 | 5,000 | $13,200 | 0 | $0 | 0 | $0 |
| 2010-08 | 5,000 | $11,450 | 0 | $0 | 0 | $0 |
| 2010-05 | 6,096 | $24,729 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2013-06-03 | Clement Christopher G (President) | Buy | 14,000 | .71 | 9,982 |
| 2013-05-30 | Cochrane Haywood D (Director) | Buy | 10,000 | .70 | 7,000 |
| 2013-05-23 | Heady Timothy James (Director) | Buy | 10,000 | .75 | 7,480 |
| 2013-05-17 | Drutz David (CEO and CMO) | Buy | 25,000 | .70 | 17,450 |
| 2012-09-17 | Drutz David (CEO and CMO) | Buy | 25,000 | 1.06 | 26,500 |
| 2012-09-11 | Cochrane Haywood D (Director) | Buy | 2,800 | .82 | 2,296 |
| 2012-09-10 | Cochrane Haywood D (Director) | Buy | 2,200 | .78 | 1,716 |
| 2012-07-20 | Cochrane Haywood D (Director) | Buy | 9,000 | .73 | 6,579 |
| 2012-07-19 | Cochrane Haywood D (Director) | Buy | 1,000 | .74 | 745 |
| 2012-06-08 | Drutz David (CEO and CMO) | Buy | 25,000 | .77 | 19,250 |
| 2012-05-29 | Drutz David (CEO and CMO) | Buy | 25,000 | .90 | 22,525 |
| 2011-04-26 | Franco Richard A (President & CEO) | Buy | 3,500 | 2.78 | 9,730 |
| 2010-09-02 | Franco Richard A (President & CEO) | Buy | 5,000 | 2.64 | 13,200 |
| 2010-08-31 | Franco Richard A (President & CEO) | Buy | 5,000 | 2.29 | 11,450 |
| 2010-05-24 | Franco Richard A (President & CEO) | Buy | 2,000 | 4.18 | 8,360 |
| 2010-05-20 | Franco Richard A (President & CEO) | Buy | 1,000 | 4.45 | 4,450 |
| 2010-05-19 | Franco Richard A (President & CEO) | Buy | 3,096 | 3.85 | 11,919 |
Insider trading activities including stock purchases, stock sales, and option exercises of POTP listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Point Therapeutics Inc (symbol POTP, CIK number 919745) see the Securities and Exchange Commission (SEC) website.